Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ding, Xueli
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis Safety and efficacy data from LUCENT-2 trial for ulcerative colitis Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis	Active, not recruiting	3	1177	Europe, Canada, Japan, US, RoW	Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC	Eli Lilly and Company	Ulcerative Colitis	11/21	12/24
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice	Completed	N/A	500	RoW		Takeda	Colitis, Ulcerative, Crohn Disease	07/24	07/24